- What Is INVIMA and What Does It Regulate?
- INVIMA Clinical Trial Approval Timeline
- Required Documents for INVIMA Clinical Trial Submission
- Common Causes of Delay in INVIMA Approvals
- How Colombia Compares to Other LATAM Jurisdictions
- What to Do If Colombia Is Still the Right Fit
- FAQs
- Plan Your Timeline Around the Approval Process, Not After It
Colombia is one of the most frequently considered Latin American markets for clinical trial expansion. It has a large patient population, established academic medical centers, and a reasonably mature research infrastructure. But for MedTech and biopharma sponsors evaluating where to run a first-in-human or early-feasibility study, INVIMA's approval process carries a reputation worth examining honestly before you commit budget and timeline to it.
This article covers how INVIMA clinical trial approvals actually work, what documents you need, how long the process takes, and where sponsors most often lose weeks or months to delays that could have been avoided.
What Is INVIMA and What Does It Regulate?
INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia's national health regulatory authority. It oversees clinical trial authorization for drugs, biologics, and medical devices conducted on Colombian territory.
For clinical research, INVIMA operates under Decree 2378 of 2008 and Resolution 8430 of 1993, which establish the ethical and scientific framework for human research in Colombia. Device trials also intersect with INVIMA's medical device registration framework, adding a classification review layer depending on the investigational product.
INVIMA is not a passive registry. It conducts substantive scientific review of protocols — which is one reason timelines run longer than sponsors sometimes expect when they first look at Colombia as a LATAM option.
INVIMA Clinical Trial Approval Timeline
INVIMA's official review window is 30 to 60 business days from the date of an accepted submission. In practice, sponsors should plan for 4 to 9 months total elapsed time — from initial submission to authorization — once you account for document preparation, parallel institutional ethics committee (IEC) review, query resolution, and any resubmission cycles.
Here is how the timeline typically breaks down:
Pre-Submission and Document Preparation
Assembling the dossier usually takes 4 to 8 weeks before submission. This phase is consistently underestimated. Missing or incorrectly formatted documents are the single most common source of delay, and INVIMA will not begin its substantive review until the submission passes an administrative completeness check.
Institutional Ethics Committee (IEC) Review
Colombia requires IEC approval from a recognized ethics committee at each participating site before INVIMA will issue final authorization. IEC timelines vary by institution but typically run 4 to 8 weeks. Some sponsors submit to both IEC and INVIMA simultaneously to compress the overall timeline; others wait for IEC approval first. Running them in parallel is more efficient, but it requires your protocol and consent forms to be finalized before either submission goes in.
INVIMA Scientific Review
Once the submission is accepted, INVIMA's scientific review team evaluates the protocol, investigator qualifications, site suitability, and the study's risk-benefit profile. This phase generates formal queries — called requerimientos — that the sponsor must respond to within a defined window. A single query round can add 4 to 8 weeks, and complex protocols sometimes generate two rounds.
Authorization Issuance
After satisfactory responses to all queries, INVIMA issues the clinical trial authorization. No subjects can be enrolled until this document is in hand.
Required Documents for INVIMA Clinical Trial Submission
The exact document list varies depending on whether the study involves a drug, biologic, or medical device, but the core dossier for most clinical trials includes:
- Clinical study protocol (in Spanish or with a certified Spanish translation)
- Investigator's Brochure (IB) or equivalent device description document
- Informed consent form(s) in Spanish, compliant with Resolution 8430
- Investigator CVs for principal investigators at each site
- Site qualification documentation (infrastructure, equipment, staff)
- Ethics committee approval letter from the IEC at each participating site
- Sponsor authorization letter and legal representation documentation for the sponsor's local representative or CRO
- Product dossier including manufacturing information, quality data, and preclinical safety summary
- Insurance or indemnification documentation covering trial participants
- INVIMA application form completed in the required format
For medical device trials specifically, INVIMA may also request the device's risk classification under Colombian regulation and, in some cases, prior regulatory clearance or CE/FDA status as supporting context.
All documents must be submitted through INVIMA's digital platform (VUE, Ventanilla Única Empresarial) in the required format. Paper submissions are no longer accepted for most trial types.
Common Causes of Delay in INVIMA Approvals
Knowing where approvals stall is more useful than knowing the official timeline. These are the delays sponsors run into most often:
Incomplete or Incorrectly Formatted Submissions
INVIMA's administrative completeness check is strict. A missing document, an incorrectly formatted file, or a translation that does not meet certification standards will result in the submission being returned. The review clock does not start until the submission clears this check.
Protocol Language and Translation Quality
The protocol and consent forms must be in Spanish. Machine-translated documents or low-quality translations regularly generate queries during scientific review — and errors in technical terminology can raise substantive scientific questions that take multiple rounds to resolve.
Ethics Committee Timing Misalignment
If IEC review at a site is delayed, INVIMA will not issue final authorization even if its own review is complete. Sponsors who treat IEC review as a sequential step after INVIMA review, rather than a parallel track, routinely add 6 to 10 weeks to their overall timeline.
Query Response Delays
INVIMA's formal queries must be answered within a specified window. Sponsors who are not organized to respond quickly — or who need to revise the protocol to address a query — can lose significant time. Each query round resets a portion of the review clock.
Investigator and Site Documentation Gaps
INVIMA scrutinizes investigator qualifications carefully. CVs that do not reflect relevant therapeutic area experience, or sites that lack documented GCP training records, frequently generate queries or requests for additional information.
Regulatory Classification Uncertainty for Devices
For medical device trials, INVIMA's classification of the investigational device under Colombian regulation can introduce uncertainty. If the device does not map cleanly to an existing Colombian classification, INVIMA may request additional technical documentation before proceeding with clinical trial review.
How Colombia Compares to Other LATAM Jurisdictions
For sponsors evaluating where to run a first-in-human or early-feasibility study, the INVIMA timeline is a meaningful planning input. The realistic 4 to 9 month window for clinical trial authorization in Colombia is significantly longer than what sponsors can achieve in certain other Latin American jurisdictions.
In Panama, El Salvador, Chile, and the Dominican Republic, ethics and regulatory approvals are typically observed in 30 to 90 days. That gap matters when your runway is tied to a Series A milestone or a board deadline. A 6-month difference in regulatory approval timing can determine whether you have data in hand before your next funding round closes.
This is one reason sponsors working with bioaccess® on FIH programs operate in those four jurisdictions rather than Colombia. The faster approval windows are not a workaround — Panama, El Salvador, Chile, and the Dominican Republic are established regulatory environments with qualified sites and data structured for FDA acceptance under 21 CFR 812.28 for foreign clinical data.
What to Do If Colombia Is Still the Right Fit
Some sponsors have specific reasons to run in Colombia: existing investigator relationships, a patient population with particular disease prevalence, or a market access strategy that makes Colombian data valuable beyond the FIH milestone. If that describes your situation, the practical steps to minimize delay are:
- Start document preparation 3 to 4 months before your target submission date. Certified translations and site qualification packages take longer than most teams expect.
- Run IEC and INVIMA submissions in parallel. Coordinate with your sites so ethics committee submissions go in at the same time as your INVIMA dossier.
- Engage a local regulatory affairs consultant or CRO with active INVIMA experience. Familiarity with current query patterns and administrative requirements is worth more than general LATAM regulatory knowledge.
- Finalize your protocol before submission. Amendments after submission restart portions of the review process.
- Build query response capacity into your team. Assign a dedicated person to monitor INVIMA communications and coordinate responses within the required window.
FAQs
What is the official INVIMA review timeline for clinical trial authorization?
INVIMA's official review window is 30 to 60 business days from the date of accepted submission. In practice, total elapsed time from initial submission to authorization is typically 4 to 9 months when accounting for document preparation, IEC review, and query resolution rounds.
Does Colombia require ethics committee approval before INVIMA authorization?
Yes. INVIMA requires IEC approval from a recognized institutional committee at each participating site as part of the authorization process. Running IEC and INVIMA submissions in parallel is the most efficient way to manage overall timeline.
What language must clinical trial documents be submitted in for INVIMA?
The protocol, informed consent forms, and most supporting documents must be in Spanish. Certified translations are required for documents originally prepared in other languages. Low-quality translations are a common source of queries and delays.
Can a foreign sponsor submit directly to INVIMA without a local representative?
No. Foreign sponsors must designate a local legal representative in Colombia or engage a CRO with local legal standing to submit and manage the application on their behalf.
What is the most common reason INVIMA submissions are delayed?
Incomplete or incorrectly formatted submissions that fail the administrative completeness check are the most frequent cause. This prevents the substantive review clock from starting and can add weeks to the process before the sponsor receives any feedback.
How does INVIMA's timeline compare to other Latin American jurisdictions?
Colombia's realistic 4 to 9 month window is longer than what is achievable in jurisdictions like Panama, El Salvador, Chile, and the Dominican Republic, where ethics and regulatory approvals are typically observed in 30 to 90 days for clinical trials in those markets.
Is INVIMA clinical trial data accepted by the FDA?
Foreign clinical data submitted to the FDA must meet the requirements of 21 CFR 812.28 for investigational devices, or equivalent standards for drugs and biologics. Whether INVIMA-authorized Colombian trial data satisfies those requirements depends on study design, ICH-GCP compliance, and the specific submission context. Sponsors should confirm FDA alignment before initiating any study intended to support a US regulatory pathway.
Plan Your Timeline Around the Approval Process, Not After It
INVIMA is a capable regulatory authority, and Colombia is a legitimate clinical research market. But the approval timeline is not forgiving of late starts or incomplete submissions. If you are managing a startup runway, a 4 to 9 month regulatory approval window needs to be factored into your FIH planning from the moment you begin site selection — not after your protocol is finalized.
If your primary goal is getting first human data within a timeline that works for your next funding round, it is worth understanding all your jurisdiction options in Latin America before defaulting to Colombia. Learn more at bioaccessla.com.
WordPress category: Navigating Regulatory Landscapes in Latin America
Leave a Reply